Sana Biotechnology

SANA

Market cap $1.26B

SEATTLE, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT on Wednesday, January 14, 2026. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.

Genomics advances are reshaping drug discovery, with Pacific Biosciences of California emerging as a key player in next-gen sequencing.

Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine Models Using Fusogen Technology

Sana Biotechnology, Inc. (SANA) Presents at Evercore 8th Annual Healthcare Conference Transcript

Sana Biotechnology, Inc. (SANA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

SEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in December. The presentations will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.

Genomics gains momentum as EDIT, SANA, and PACB emerge as standout picks amid rapid advances in sequencing and gene editing.

Sana (SANA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Sana Biotechnology, Inc. remains a Strong Buy, driven by progress in HIP-modified cell therapies for Type 1 Diabetes and B-cell-mediated disorders. Sana Biotechnology's HIP-modified islet cell therapy showed a 6-month insulin response without needing immunosuppression in one T1D patient, supporting a paradigm shift in treatment. Upcoming 2025 data readouts from phase 1 GLEAM (SC291, autoimmune disorders) and VIVID (SC262, B-cell malignancies) trials are key catalysts for Sana Biotechnology.

Sana Biotechnology, Inc. surged after hedge fund manager Eric Jackson called it a potential "100-bagger" due to its pioneering diabetes cell therapy. Sana Biotechnology's breakthrough islet cell therapy, using proprietary hypoimmune technology, enabled insulin production in a type 1 diabetes patient without immunosuppression. Significant challenges remain: scalable cell manufacturing, safe and scalable administration, and massive funding needs before commercial viability is achieved.